Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

UK among worst offenders in G7 vaccine supply failures ‘which led to 600,000 preventable deaths’

With days left until Britain reaches the deadline to fulfil its 100 million dose pledge, only 39 per cent have actually been delivered

The Independent UK

Pfizer says its tweaked COVID-19 shots boost protection against the omicron variant

Pfizer said that tweaking its vaccine to better target the omicron variant is safe and works — just days before regulators debate whether to offer Americans updated booster shots this fall.

WEKU

Pfizer says tweaked COVID-19 shots boost omicron protection

Pfizer says tweaking its COVID-19 vaccine to better target the omicron variant is safe and boosts protection

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna COVID-19 shots now an option for older kids in US

There is now a second COVID-19 option for kids ages 6 to 17 in the U.S. The Centers for Disease Control and Prevention on Friday announced it is recommending Moderna shots as an option for school-age kids and teens

The Independent UK

Moderna Has Multi-Billion-Dollar Opportunity Outside Of COVID-19 Vaccines, Analyst Says

Moderna, Inc. (NASDAQ: MRNA) rose to prominence with its messenger RNA-based COVID-19 vaccine.

Benzinga

Experts endorse Moderna COVID-19 shots for kids ages 6 to 17

An expert panel backed a second COVID-19 vaccine option for kids ages 6 to 17

The Independent UK

Research behind COVID vaccines reaps close to $1 billion in royalties for Penn

PHILADELPHIA — The University of Pennsylvania has reaped extraordinary financial gain from COVID-19 vaccines — approaching $1 billion since the beginning of last year — thanks to patents on a process Penn researchers developed more than 15 years ago.

The Philadelphia Inquirer

Read news from The Economist, FT, and more,
with one subscription

Moderna confirms two-in-one Covid and flu jab in the works as testing under way

Scientists have developed an alternative to the current separate inoculations with the trial already under

Daily Record

This Is What Whales Are Betting On Moderna

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Young adults and children should get Covid booster jabs this autumn, vaccine chiefs warn

The announcement comes after the UK is seeing a spike in Covid-19 cases and follows a trial of Moderna's new vaccine designed to tackle the more contagious sub-variants of Omicron

Daily Mirror

Two-in-one covid and flu jab in pipeline with testing under way

Vaccination developer Moderna is calling for action on the current jab programme warning people could find themselves 'under-protected and under-vaccinated'

Wales Online

So What's Going On With Moderna Shares Rising Today?

Moderna Inc (NASDAQ: MRNA) shares are trading higher after the company released data on its bivalent COVID booster candidate. Data showed potent neutralizing antibody responses against the omicron subvariants BA.4 and BA.5.

Benzinga

Moderna to build UK’s first mRNA vaccine research and manufacturing centre

US biotech firm agrees £1bn deal with government for centre to combat Covid and other illnesses

The Guardian - UK

Call for autumn booster programme to be extended

It comes as Moderna announced that its variant vaccine can create a strong antibody response to the BA.4 and the BA.5 variants.

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Los Angeles Times

2 million California kids are now eligible for COVID vaccine. How many will get it?

LOS ANGELES — Jonah Stein exited the vaccination clinic in his father’s arms Tuesday afternoon, proud to show off his Band-Aid.

Benzinga

Moderna's Bivalent COVID-19 Booster Shows Antibody Response Against Omicron Subvariants

Moderna Inc (NASDAQ:MRNA) has released new clinical data on its bivalent (omicron) COVID booster candidate, mRNA-1273.214. One month after administration in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited potent neutralizing antibody responses against the omicron subvariants BA.4 and BA.5. The company is working on completing regulatory submissions…

Benzinga

Benzinga Before The Bell: Executive Shakeup At Amazon, Boeing Supply Chain Warning, Apple's Tim Cook Says 'Stay Tuned' On AR/MR And Other Top Financial Stories Wednesday, June 22

CNBC Moderna To establish New Vaccine Facility In Britain

Benzinga

Moderna To establish New Vaccine Facility In Britain

Moderna Inc (NASDAQ:MRNA) announced an agreement with the United Kingdom government to establish an mRNA Innovation and Technology Center in the U.K. Additionally, Moderna plans to expand its presence in the U.K. through investments in R&D activities. Moderna is collaborating with the National Institute for Health Research on a Phase 3 study…

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Government’s Moderna partnership to bring over £1 billion investment

A partnership to open a new research and manufacturing centre in the UK will mean over £1 billion in mRNA research investment.

ABC News

COVID-19 vaccine from Moderna 'provides good clinical protection' against Omicron subvariants

The biotech company's experimental Omicron booster generates high levels of antibodies that neutralise subvariants BA.4 and BA.5, according to preliminary clinical trial data.

WEKU

COVID vaccines are finally here for young kids. But the logistics aren't easy

NPR talks to Claire Hannan, who has helped navigate vaccine rollouts in all 50 states, about some of the challenges involved in quickly getting shots out to millions of young kids.

Reuters

COVID-19 vaccine scheme for world's poorest pushes for delivery slowdown

Leaders of the global scheme aiming to get COVID-19 vaccines to the world's poorest are pushing manufacturers including Pfizer and Moderna to cut or slow deliveries of about half a billion shots so doses are not wasted.

The Independent UK

Moderna unveils plans for research and manufacturing centre in the UK

It is hoped British patients will be able to benefit from new developments in mRNA technology.

The Independent UK

Shots for tots: COVID vaccinations start for little US kids

The nation’s youngest children are getting their chance at vaccines for COVID-19

Tribune News Service

US panel backs Moderna, Pfizer COVID shots for youngest kids

Infants and toddlers in the U.S. are now able to be vaccinated against COVID-19 after shots from Moderna Inc. and Pfizer Inc. won support from health advisers on Saturday.

1 … 22 23 24 25

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations